Until 2022, there was not a single FDA-approved systemic treatment for alopecia areata. Practitioners managed this condition with off-label corticosteroids, immunotherapy with DPCP, and a lot of uncertainty. Clients with severe AA, those who had lost fifty percent or more of their scalp hair, had almost no evidence-based options beyond waiting and hoping.
That changed fast. Between June 2022 and July 2024, the FDA approved three oral JAK inhibitors for severe alopecia areata: baricitinib, ritlecitinib, and deuruxolitinib. All three target the same core immune mechanism. All three have phase 3 trial data in large patient populations. And all three have long-term extension data showing what happens when patients stay on treatment for one to three years.
The science underneath these drugs is not complicated, but it is precise. If you see clients with alopecia areata, or if clients come to you after being prescribed one of these medications, you need to understand how they work, what the data shows, and where the limitations are. This is the breakdown.
The Immune Mechanism: Why Hair Falls Out in Alopecia Areata
Alopecia areata is an autoimmune disease. The hair follicle, under normal conditions, operates as an immune-privileged site, meaning the immune system is actively prevented from attacking it. This privilege depends on the follicle downregulating MHC class I molecules and maintaining a local anti-inflammatory microenvironment around its lower bulb during anagen.
In AA, that privilege collapses. The follicular epithelium begins presenting self-antigens through MHC class I molecules, which attracts cytotoxic CD8+ T cells bearing the NKG2D receptor. These CD8+NKG2D+ T cells recognize the follicle as a target, infiltrate the peribulbar region, and begin producing interferon-gamma. IFN-γ then does two things that make the problem self-sustaining.
IFN-γ binds to receptors on follicular epithelial cells and activates the JAK1/JAK2-STAT1 signaling cascade. This triggers the follicle to upregulate IL-15 and its receptor IL-15Rα. IL-15 signals back to the attacking T cells through JAK1/JAK3-STAT5, amplifying their activation and driving further IFN-γ production. The result is a self-reinforcing inflammatory loop: the more the follicle is attacked, the more it signals for attack. Hair growth arrests. The follicle enters a dystrophic catagen and stays there.
The landmark 2014 Nature Medicine paper from Columbia University demonstrated this mechanism definitively in both mouse models and human tissue, and showed that oral JAK inhibitors could reverse it. That paper launched the entire therapeutic pipeline that led to the three drugs now on the market.
Baricitinib: The First Approval
Baricitinib (Olumiant, Eli Lilly) is a JAK1/JAK2 inhibitor. It was already approved for rheumatoid arthritis and had an established safety database. In June 2022, it became the first drug ever approved by the FDA for adults with severe alopecia areata, based on two phase 3 trials: BRAVE-AA1 and BRAVE-AA2.
BRAVE-AA1 enrolled 654 patients and BRAVE-AA2 enrolled 546, all with SALT scores of 50 or higher, meaning at least 50% scalp hair loss. At 36 weeks, 35 to 40 percent of patients receiving baricitinib 4 mg daily achieved a SALT score of 20 or less, meaning 80% or more scalp coverage. That is a meaningful clinical response from a condition that previously had no systemic treatment.
The 104-week extension data, published in the Journal of the European Academy of Dermatology and Venereology in 2024, showed something equally important: durability. Among patients who achieved SALT ≤20 at week 52 on the 4 mg dose, 90.7% maintained that response at week 104. The drug keeps working when patients stay on it.
Three-year safety data published in the American Journal of Clinical Dermatology in 2025 confirmed no new safety signals over a median 2.3 years of treatment. Serious adverse events were uncommon, and no cases of major adverse cardiovascular events, deep vein thrombosis, or pulmonary embolism were observed in the AA population. That last point matters because JAK inhibitors carry a class-wide boxed warning based on data from older rheumatoid arthritis populations, and the AA safety profile appears distinct from that context.
Ritlecitinib: JAK3 and the TEC Family Kinases
Ritlecitinib (Litfulo, Pfizer) is different from baricitinib in one important respect: it selectively inhibits JAK3 and the TEC family of kinases rather than JAK1/JAK2. This means it targets the T-cell side of the feedback loop more specifically, blocking the IL-15 signaling axis that drives CD8+NKG2D+ T cell activation without broadly suppressing JAK1/JAK2-mediated pathways involved in hematopoiesis and other immune functions.
The FDA approved ritlecitinib in June 2023 for adults and adolescents aged 12 and older with severe alopecia areata. That adolescent indication matters. It remains the only JAK inhibitor approved for pediatric AA patients.
The ALLEGRO-LT long-term extension study enrolled 449 de novo patients receiving ritlecitinib 50 mg daily following a 200 mg loading dose for the first four weeks. At 24 months, 73.5% of patients achieved SALT ≤20, and 66.4% achieved SALT ≤10, meaning 90% or more scalp coverage. Those are striking long-term response rates, substantially higher than the initial 24-week data, which indicates that ritlecitinib's efficacy continues to build over time for many patients.
The safety profile at 24 months was consistent with earlier data. The most common adverse events were headache, acne, and nasopharyngitis. Serious adverse events occurred in 4.9% of patients. No major cardiovascular events or thromboembolic events were reported.
Ritlecitinib uses a 4-week loading phase at 200 mg daily before stepping down to 50 mg maintenance. The rationale is rapid suppression of the T-cell inflammatory loop in the peribulbar space. Analyses from the ALLEGRO program show that patients with less extensive hair loss at baseline tended to respond faster and more completely, suggesting that early intervention before the immune infiltrate becomes deeply entrenched may improve outcomes. A phase 3 trial evaluating 100 mg as a higher maintenance dose is currently underway.
Deuruxolitinib: The Newest Entrant
Deuruxolitinib (Leqselvi, Sun Pharma) was approved by the FDA in July 2024 for adults with severe alopecia areata. It is a selective JAK1/JAK2 inhibitor, mechanistically similar to baricitinib but chemically distinct, dosed at 8 mg twice daily. It became commercially available in the United States in mid-2025.
The approval was based on two phase 3 trials, THRIVE-AA1 and THRIVE-AA2, enrolling a combined 1,220 patients with baseline SALT scores averaging 86 to 88, representing near-total scalp hair loss.
At 24 weeks, 29.6% of patients on the 8 mg dose and 41.5% on the 12 mg dose achieved SALT ≤20. Long-term extension data presented at the 2024 Fall Clinical Dermatology Conference showed continued improvement: by week 68, 48.8% of patients had achieved SALT ≤20, and 99.6% of initial responders maintained their response. Like the other two drugs, deuruxolitinib's efficacy appears to deepen over time.
Comparative Efficacy: What the Meta-Analyses Say
No head-to-head randomized trials comparing baricitinib, ritlecitinib, and deuruxolitinib exist. The best available evidence comes from network meta-analyses, which use statistical modeling to compare treatments indirectly through their respective placebo-controlled trials.
A 2025 Bayesian network meta-analysis incorporating seven randomized controlled trials and over 4,500 patients found that deuruxolitinib 8 mg twice daily demonstrated the highest probability of achieving SALT ≤20 and SALT ≤10 at 24 weeks among the three approved drugs. The differences between deuruxolitinib and ritlecitinib were directionally favorable for deuruxolitinib but did not reach statistical significance. Both outperformed baricitinib at its approved doses on short-term efficacy endpoints.
Context matters when interpreting these comparisons. The BRAVE, ALLEGRO, and THRIVE trials used somewhat different patient populations, disease durations, and dosing protocols. Short-term efficacy at 24 weeks tells you one thing. Long-term response at 24 months tells you something different. Ritlecitinib's 73.5% SALT ≤20 at 24 months is the highest published long-term rate among the three drugs, but this reflects an open-label extension cohort rather than a head-to-head comparison. The honest answer is that all three drugs work, and individual patient response will vary.
Safety: The Class-Wide Context
All oral JAK inhibitors carry an FDA boxed warning for increased risks of serious infections, major adverse cardiovascular events (MACE), thrombosis, malignancy, and mortality. This warning stems primarily from the ORAL Surveillance study of tofacitinib in rheumatoid arthritis patients aged 50 and older with cardiovascular risk factors.
The AA-specific safety data tells a different story. Patients with alopecia areata are typically younger and healthier than the RA population. Across the BRAVE, ALLEGRO, and THRIVE programs, no signal for MACE, deep vein thrombosis, or pulmonary embolism has emerged in thousands of patient-years of exposure. The baricitinib program now has safety data extending beyond four years of treatment.
The boxed warning applies to the drug class, not specifically to the AA indication or patient population. Prescribing decisions belong to the dermatologist or prescribing physician. Trichologists should understand the distinction, be able to explain to clients that the warning reflects data from a different patient population, and avoid both minimizing and catastrophizing the risk. Direct clients to their prescribing physician for individualized risk assessment. That is the appropriate boundary.
The most common adverse events across all three drugs are headache, upper respiratory infections, acne, and nasopharyngitis. Lab monitoring for complete blood count, hepatic function, and lipid panels is standard across prescribing protocols. Herpes zoster reactivation has been observed at rates slightly above background, and vaccination status should be reviewed before initiation.
What Happens When You Stop
This is the question that matters most to clients, and the answer is honest but difficult: alopecia areata typically relapses when JAK inhibitors are discontinued. The BRAVE-AA1 withdrawal study published in JAMA Dermatology showed that the majority of patients who discontinued baricitinib experienced recurrence of hair loss, though some maintained partial response for weeks to months before relapsing.
This is consistent with the immunology. JAK inhibitors suppress the inflammatory loop. They do not cure the underlying autoimmune predisposition. As long as the follicular immune privilege remains vulnerable to collapse, stopping the drug removes the brake on T-cell-mediated attack. This makes JAK inhibitors a chronic maintenance therapy for most patients, similar to how minoxidil works for pattern hair loss. That framing helps set realistic expectations.
What This Means for Trichologists
Understand the mechanism at the cellular level. When clients ask you about these drugs, or when they come to you already taking one, you should be able to explain the IFN-γ/JAK-STAT positive feedback loop, why the follicle's immune privilege breaks down, and why blocking that loop restores hair growth. You are not prescribing these medications, but you are the professional your client may trust most to explain what is happening to their hair.
Know which drug is which. Baricitinib and deuruxolitinib target JAK1/JAK2. Ritlecitinib targets JAK3 and TEC kinases. The clinical implications of that difference are still being worked out, but the selectivity profiles matter for understanding side effect patterns and why different patients may respond to different agents.
Recognize the adjunctive role. JAK inhibitors address the immune attack on the follicle. They do not address follicle miniaturization, nutritional deficiencies, or the scalp environment. A client on baricitinib who also has iron-deficiency telogen effluvium, or seborrheic dermatitis, or traction from styling practices, still needs those issues managed. Your scope of practice as a trichologist encompasses exactly those factors. These drugs work alongside what you do, not instead of it.
Prepare for the relapse conversation. Clients who achieve dramatic regrowth on a JAK inhibitor will eventually face the question of what happens if they stop. Some will choose to stay on medication indefinitely. Others will want to taper or discontinue. You should be prepared to support them through potential relapse with honest communication and a clear understanding of what the evidence shows about treatment duration and withdrawal outcomes.
This is not going away. The JAK inhibitor pipeline for AA includes higher-dose formulations, topical JAK inhibitors in development, combination protocols, and emerging agents like upadacitinib now in phase 3 trials. The treatment landscape for alopecia areata has fundamentally changed, and the evidence base is going to keep growing. Staying current on this science is not optional for any practitioner who sees clients with autoimmune hair loss.
The Bottom Line
Three oral JAK inhibitors are now FDA-approved for severe alopecia areata: baricitinib (2022), ritlecitinib (2023), and deuruxolitinib (2024). All three work by disrupting the IFN-γ/JAK-STAT positive feedback loop between follicular epithelium and CD8+NKG2D+ cytotoxic T cells that drives immune privilege collapse. Phase 3 trials enrolling thousands of patients demonstrate meaningful hair regrowth, with long-term data showing response rates climbing over 12 to 24 months of continuous treatment. Network meta-analyses suggest slight efficacy differences between agents at 24 weeks, but all three are effective. The drugs suppress the autoimmune attack rather than cure it, meaning relapse is expected upon discontinuation for most patients. Trichologists need to understand this mechanism, know the evidence, and be prepared to support clients navigating a treatment landscape that did not exist four years ago.